Quanterix Corporation to Release Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022

On February 23, 2022 Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, reported that it will release its financial results for fourth quarter 2021 before the start of trading on Tuesday, March 1, 2022 (Press release, Quanterix, FEB 23, 2022, View Source [SID1234608913]). Company management will host a conference call at 8:30 a.m. EST to discuss Quanterix’ financial results and provide a business update. The call will be hosted by Kevin Hrusovsky, Chairman and Chief Executive Officer, Quanterix.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Individuals interested in listening to the conference call may do so by dialing (833) 686-9351 for domestic callers, or (612) 979-9890 for international callers. Please reference the following Conference ID: 5230769. A live webcast will also be available at: View Source You may also access the live webcast by visiting the News & Events page within the Investors section of the Quanterix website at www.quanterix.com. The webcast will be available on the Company’s website for one year following completion of the call.

CytomX Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022

On February 22, 2022 CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, reported that it will report fourth quarter and full year 2021 financial results on Tuesday, March 1, 2022, after the close of U.S. markets (Press release, CytomX Therapeutics, FEB 22, 2022, View Source [SID1234608798]). Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results and provide a corporate update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX’s website at View Source An archived replay of the webcast will be available on the Company’s website until March 8, 2022.

Syndax to Announce Fourth Quarter and Year-end 2021 Financial Results and Host Conference Call and Webcast on March 1, 2022

On February 22, 2022 Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, reported that it will release its fourth quarter and year-end 2021 financial results on Tuesday, March 1, after the close of the U.S. financial markets (Press release, Syndax, FEB 22, 2022, View Source [SID1234608814]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In connection with the earnings release, Syndax’s management team will host a conference call and live audio webcast at 4:30 p.m. ET on Tuesday, March 1, to discuss the Company’s financial results and provide a general business update.

The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company’s website at www.syndax.com. Alternatively, the conference call may be accessed through the following:

City of Hope awarded $4.9 million from CIRM to train future leaders in stem cell biology and regenerative medicine

On February 22, 2022 City of Hope, one of the largest cancer research and treatment organizations in the United States and a leading research center for diabetes and other life-threatening illnesses, reported that its Department of Stem Cell Biology and Regenerative Medicine received a $4.9 million grant to train the next generation of scientific leaders in basic stem cell research and its translation into novel, lifesaving treatments (Press release, City of Hope, FEB 22, 2022, View Source [SID1234608832]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The award from the California Institute for Regenerative Medicine (CIRM) contributes to the more than $121 million in grants that Beckman Research Institute of City of Hope has received from CIRM to date, indicating the state-funded agency’s confidence in City of Hope’s long-standing leadership in stem cell-related therapies. As a biomedical institution, City of Hope has deep expertise in developmental and stem cell biology, resulting in strong clinical programs in bone marrow transplantation, cancer immunotherapy, gene therapy to correct genetic defects, and cell replacement and tissue regeneration strategies to treat diabetes.

"Our mission is to train predoctoral and postdoctoral CIRM scholars in basic stem cell and developmental biology, and the translation of this foundational knowledge into novel and effective therapies for patients with cancers, degenerative diseases, genetically caused conditions and other maladies," said Michael Barish, Ph.D., professor in the Department of Stem Cell Biology and Regenerative Medicine and program director of the CIRM-funded educational project.

The five-year grant will be used to mentor junior scientists with the help of City of Hope’s Irell & Manella Graduate School of Biological Sciences at Beckman Research Institute. The program will leverage City of Hope’s position as one of the few cancer centers in the United States with on-campus good manufacturing practice facilities capable of creating clinical-grade biologics and small molecules. Lastly, students will benefit from the fact that their classrooms and laboratories are within walking distance from where patients receive compassionate patient care.

City of Hope has an integrated, multidisciplinary approach to translating fundamental research findings into clinical practice for patients’ benefit. In addition to laboratory research, the CIRM scholars will learn how to implement cell-based therapies, engineer and manufacture cells, obtain regulatory approval and commercialize biomedical products. Instruction will come from scientific and clinical faculty, research nurses and experts in the ethics of stem cell research and its application to medicine.

Due to the program’s proximity to patient care areas, students will also have the unique opportunity to receive mentorship from both City of Hope’s Department of Supportive Care Medicine and Division of Health Equities, where they will be exposed to experts in patient engagement and community outreach programs.

"This program originates from City of Hope’s longstanding expertise in conducting clinical trials and applying fundamental stem cell biology and gene therapy to the treatment of diseases. The program reflects City of Hope’s commitment to ensuring that future scientific leaders understand the varied needs of diverse patient populations, and the inequities that presently affect both biomedical research and the development of and access to innovative therapies," said Nadia Carlesso, M.D., Ph.D., professor and chair of the Department of Stem Cell Biology and Regenerative Medicine and co-investigator of the CIRM project.

Other leaders in this CIRM-funded stem cell and regenerative medicine training program include City of Hope’s Yanhong Shi, Ph.D., Herbert Horvitz Professor in Neuroscience, Rick Kittles, Ph.D., M.S., professor and director of the Division of Health Equities, and Keely Walker, Ph.D., director of the Office of Faculty and Institutional Support.

The new program is one element of City of Hope’s broad commitment to education, including the Irell & Manella Graduate School of Biological Sciences at Beckman Research Institute, which offers doctoral programs in biological sciences and translational medicine, as well as master’s programs in regulatory affairs and translational medicine. City of Hope also supports a portfolio of National Cancer Institute-supported training programs in cancer metabolism, DNA damage and pathways to cancer, as well as training programs for students from traditionally underrepresented backgrounds (supported by the National Institute of Diabetes and Digestive and Kidney Diseases).

Apollo Therapeutics and King’s College London Enter Into a Strategic Collaboration

On February 22, 2022 Apollo Therapeutics, a biopharmaceutical company focused on translational biology and asset-centric drug development, and King’s College London, reported the formation of a new strategic collaboration (Press release, Apollo Therapeutics, FEB 22, 2022, View Source [SID1234608363]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The collaboration will leverage the distinct strengths of each organization with a focus on developing novel therapeutics for patients across multiple disease areas. King’s has one of the leading scientific discovery portfolios worldwide and will contribute biological research breakthroughs with the potential to create high-impact medicines. In addition, the university’s associated hospitals and clinician scientists are ideally positioned to provide support to programs during clinical development. Apollo’s translational scientists and drug development architects will progress these research programs under Apollo’s asset-centric portfolio model to rapidly and efficiently bring those with the greatest promise through clinical investigation and ultimately to patients.

"Translating our biomedical research into effective therapies that improve health is a key priority for King’s researchers. I am delighted that this new partnership with Apollo will provide new routes for us to achieve this goal," said Professor Reza Razavi, Vice President (Research) at King’s College London. "Apollo has an excellent track record in partnering with academics to progress their discoveries into therapies. King’s researchers are looking forward to working with Apollo to progress promising therapeutic programs into their drug discovery pipeline and on to clinical impact."

"When looking at research output, King’s College London is one of the largest and most successful centers for biomedical research and education in the UK and indeed globally. With its broad clinical presence, we have also found King’s has exceptional insight in selecting and advancing research that can translate effectively into therapeutic programs," said Dr. Richard Mason, chief executive officer of Apollo. "We are proud to initiate this partnership with our newest collaborator as we look to grow both our portfolio of programs and our relationships with the world’s leading scientists and biomedical institutions. This collaboration continues to build on recent the progress we have made in advancing our internal pipeline, building our team and establishing our US operations in Cambridge, Mass."

King’s College London joins Apollo alongside other top global research partners, Imperial College London, University College London, and the University of Cambridge.